2022
Tobacco use patterns and clinical outcomes in the T1D exchange
Rash CJ, Alessi SM, Foster N, Tamborlane W, Van Name MA, Wagner JA. Tobacco use patterns and clinical outcomes in the T1D exchange. Journal Of Diabetes And Its Complications 2022, 36: 108128. PMID: 35058139, PMCID: PMC8881793, DOI: 10.1016/j.jdiacomp.2022.108128.Peer-Reviewed Original ResearchConceptsFormer usersTobacco useDiabetic ketoacidosis episodesTobacco cessation interventionsT1D Exchange RegistryCurrent tobacco useTobacco use patternsTobacco use statusCurrent usersSelf-reported outcomesBlood glucose monitoring frequencyCross-sectional comparisonDaily useTobacco statusClinical outcomesKetoacidosis episodesT1D ExchangeCessation interventionsBlood glucoseWorse outcomesDiabetes indicatorsNeuropathy diagnosisStandardized questionnaireMost outcomesDeleterious association
2020
Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi SM, Foster NC, Rash CJ, Van Name MA, Tamborlane WV, Cengiz E, Polsky S, Wagner J. Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange. Canadian Journal Of Diabetes 2020, 44: 501-506. PMID: 32792103, DOI: 10.1016/j.jcjd.2020.06.005.Peer-Reviewed Original ResearchConceptsBody mass indexSevere hypoglycemiaFormer drinkersLower oddsAlcohol consumptionNonbinge drinkersType 1Current binge drinkersPresence of neuropathyDiabetes-related distressDiabetes-related outcomesType 1 diabetesCross-sectional studyYears of ageNon-Hispanic whitesDiabetic ketoacidosisRecent severe hypoglycemiaMedical chartsClinical outcomesMass indexProspective studyDiabetes distressBlood glucoseBinge drinkersDrinking status
2019
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics 2019, 21: 66-72. PMID: 30657336, PMCID: PMC7061293, DOI: 10.1089/dia.2018.0384.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringT1D Exchange RegistryRegistry participantsDiabetes managementHigher mean HbA1cType 1 diabetesType 1 diabetes managementMinority of adultsProfile of adultsHbA1c goalDiabetic ketoacidosisMean HbA1cSevere hypoglycemiaClinical outcomesT1D ExchangeT1D managementAge 30Longitudinal changesADA goalsAge 28Age 15Glucose monitoringYoung adultsCGM usersRacial differences
2018
Substance Use in Adults With Type 1 Diabetes in the T1D Exchange
Petry NM, Foster NC, Cengiz E, Tamborlane WV, Wagner J, Polsky S. Substance Use in Adults With Type 1 Diabetes in the T1D Exchange. The Science Of Diabetes Self-Management And Care 2018, 44: 510-518. PMID: 30203721, DOI: 10.1177/0145721718799088.Peer-Reviewed Original ResearchConceptsType 1 diabetesGeneral populationSubstance usePast-year alcohol usePast-year usePsychoactive substancesDaily usePsychoactive substance usePast-month useClinical outcomesT1D ExchangeProblem useBinge drinkersT1D managementNonprescription useRegistry CenterAlcohol useStandardized instrumentsProblem drinkersAdult participantsDiabetesAdultsFrequency of useDrinkersProblematic useThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2016
Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study
Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, Klingensmith GJ, Gal RL, Silverstein J, Lee J, Redondo MJ, Beck RW, Consortium F. Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatric Diabetes 2016, 18: 566-573. PMID: 27758023, PMCID: PMC5397378, DOI: 10.1111/pedi.12459.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDisease ProgressionDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinInsulin SecretionInsulin-Secreting CellsMaleProspective StudiesRiskSeverity of Illness IndexUnited StatesConceptsType 1 diabetesPercentage of participantsClinical outcomesDiabetic ketoacidosisGlycemic controlResidual endogenous insulin secretionCourse of T1D.Pediatric Diabetes ConsortiumYears of diabetesOnset StudyEndogenous insulin secretionOptimal glycemic controlTime of diagnosisDuration of T1DNew insulin analoguesNovel treatment strategiesAdjunctive pharmacologic agentsFirst yearPartial remissionDiabetes CenterInsulin doseYears postdiagnosisMonths postdiagnosisGlycated hemoglobinPharmacologic agentsA cross‐sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry
Nambam B, Silverstein J, Cheng P, Ruedy KJ, Beck RW, Wadwa R, Klingensmith G, Willi SM, Wood JR, Bacha F, Thomas IH, Tamborlane WV, Consortium F. A cross‐sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry. Pediatric Diabetes 2016, 18: 222-229. PMID: 26970319, DOI: 10.1111/pedi.12377.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultChildCohort StudiesCombined Modality TherapyComorbidityCross-Sectional StudiesDiabetes Mellitus, Type 2Glycated HemoglobinHumansHyperglycemiaHypoglycemiaMedical RecordsPractice Patterns, Physicians'PrevalenceRegistriesRisk FactorsUnited StatesYoung Adult
2015
Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes
Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH. Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. Pediatrics 2015, 135: 424-434. PMID: 25687140, PMCID: PMC4533245, DOI: 10.1542/peds.2014-1774.Peer-Reviewed Original ResearchConceptsHispanic participantsEthnic disparitiesSocioeconomic statusDiabetic ketoacidosisHemoglobin A1cT1D Exchange Clinic RegistryMean hemoglobin A1cLarge pediatric cohortOptimal glycemic controlSevere hypoglycemic eventsBlack participantsType 1 diabetesMore Black participantsNon-Hispanic blacksGlycemic controlSevere hypoglycemiaClinic registryClinical outcomesPediatric cohortHypoglycemic eventsDiabetes outcomesTreatment outcomesTherapeutic modalitiesDiabetes managementDiabetes treatment
2014
Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries
Maahs DM, Hermann JM, DuBose SN, Miller KM, Heidtmann B, DiMeglio LA, Rami-Merhar B, Beck RW, Schober E, Tamborlane WV, Kapellen TM, Holl RW, for the DPV Initiative and the T1D Exchange Clinic Network. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia 2014, 57: 1578-1585. PMID: 24893863, DOI: 10.1007/s00125-014-3272-2.Peer-Reviewed Original ResearchConceptsType 1 diabetesYounger patientsClinical outcomesT1D ExchangeTreatment modalitiesGerman/Austrian DPV registryAims/hypothesisThe studyFrequency of DKAProspective Diabetes FollowImproved metabolic controlRisk of DKAYears of ageDPV registryRegistry participantsAdolescent DiabetesHypothesisThe studyInjection usersClinical careMetabolic controlFrequency of SHT1DXAge groupsInsulin pumpParticipant characteristicsType 1
2013
Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis
Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ, Consortium F. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. Pediatric Diabetes 2013, 15: 287-293. PMID: 23944865, PMCID: PMC3844085, DOI: 10.1111/pedi.12068.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsIncidenceInfantInsulinKaplan-Meier EstimateMaleProportional Hazards ModelsProspective StudiesUnited StatesConceptsPediatric Diabetes ConsortiumDiabetic ketoacidosisClinical outcomesNatural historyFirst yearCourse of T1DDiagnosis of T1D.Onset of T1DTime of diagnosisSevere hypoglycemic eventsType 1 diabetesMean HbA1cMulticenter studyHypoglycemic eventsClinical measuresLarge cohortIntervention studiesDiagnosisFuture interventionsMonthsOnset StudyHbA1cT1D.T1DOutcomes
2010
STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomes